OPTImal Management of Antithrombotic Agents: OPTIMA-2 Trial
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1724 participants.
Also called NCT01955200
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 1,724 participants
- Sponsor
- Registry
-
NCT01955200
-
- Other papers using this trial's data
- Intensified antiplatelet therapy in patients after percutaneous coronary intervention with high on-treatment platelet reactivity: the OPTImal Management of Antithrombotic Agents (OPTIMA)-2 Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT01955200. Randomized; no masking; primary purpose treatment. Start 2013-10-05 (actual); primary completion 2016-12-26 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- OPTImal Management of Antithrombotic Agents: OPTIMA-2 Trial
- Acronym
- OPTIMA-2
- Condition
- Coronary Artery Disease
- Intervention (Drug)
- Clopidogrel
- Intervention (Drug)
- Cilostazol
- Intervention (Drug)
- Ticagrelor
- Intervention (Drug)
- Clopidogrel
- Intervention (Drug)
- Clopidogrel
- Lead sponsor
- The First Affiliated Hospital with Nanjing Medical University
- Collaborator
- National Natural Science Foundation of China
Record details
- Record id
cardio:ct-nct01955200- Content hash
32d93162830acff400b03c098bafc348c67eaeae702ca0d8c08d522c91dcf98c